Search results
Added:
2 years ago
AHA 23 - Investigator, Dr Mandeep R Mehra (Brigham and Women's Hospital and Harvard Medical School, US) is joined by Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the ARIES HM3 trial.ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were…
View more
Added:
2 years ago
Source:
Radcliffe Cardiology
Find out what's hot at TCT in this preview from Prof Nicolas Van Mieghem and Dr Joost Daemen
The Cardiovascular Research Foundation (CRF) has unveiled the late-breaking clinical trials scheduled for presentation at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting taking place from October 23 to 26 in San Francisco. TCT is renowned for showcasing groundbreaking research in…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Greg GuilloryTwo late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes…
View more
Added:
1 month ago
Added:
3 weeks ago
Arrhythmia Academy Editor-in-Chief Dr Luigi Di Biase shares his expert perspective on the most practice-changing clinical trials emerging from the latest advances in atrial fibrillation management.In this highlights discussion, Dr Di Biase distills the key evidence that is reshaping clinical decision-making in AF ablation, anticoagulation strategies, and rhythm control approaches. Drawing from…
View more
Added:
3 weeks ago
Added:
10 months ago
SGLT2 Inhibitors in Acute Heart Failure
Added:
3 days ago
Viewpoint
Added:
4 months ago
TCT 2025 - In this insightful highlights video from TCT 2025, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, SA) provides expert commentary on the most impactful late-breaking clinical trials presented at this year's conference.The commentary distills the most important late-breaking trials in structural cardiology, coronary interventions, and artificial intelligence presented at TCT 2025…
View more
Added:
4 months ago
TCT 2025 - Long-term follow-up of the PARTNER 3 trial showed no safety concerns for transcatheter aortic-valve replacement (TAVR) compared to surgical treatment of aortic stenosis (AS).Dr Michael Mack (Baylor Scott & White Heart Hospital, Plano, US) joins us to share the clinical and echocardiographic outcomes from the seven-year follow-up of the PARTNER 3 low-risk randomised trial (NCT02675114)…
View more